The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, ...
Medpage Today on MSN13h
ASA Advises No Longer Holding GLP-1 Agents Prior to Surgery for Most PatientsMost patients should not stop taking GLP-1 receptor agonists prior to elective surgery, according to updated guidance from several medical societies, including the American Society of ...
Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing ...
Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing ...
News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to ...
As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...
A large retrospective study, the first of its kind, reported reduced rates of EO-CRC in patients younger than 50 years of age ...
When food enters the digestive system, specialized cells in the small intestine release GLP-1, initiating a cascade of ...
While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs ...
HealthDay on MSN1d
Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in SurgeriesAmong privately insured patients, there was a doubling in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback